nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—AGTR1—pancreatic cancer	0.892	1	CbGaD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—SSTR3—pancreatic cancer	0.00188	0.0323	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—SSTR1—pancreatic cancer	0.0018	0.031	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—SSTR2—pancreatic cancer	0.00174	0.0298	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CCKBR—pancreatic cancer	0.00168	0.0288	CbGpPWpGaD
Azilsartan medoxomil—Tasosartan—AGTR1—pancreatic cancer	0.00165	0.235	CrCbGaD
Azilsartan medoxomil—Olmesartan—AGTR1—pancreatic cancer	0.0014	0.199	CrCbGaD
Azilsartan medoxomil—Telmisartan—AGTR1—pancreatic cancer	0.00135	0.192	CrCbGaD
Azilsartan medoxomil—Hyperuricaemia—Sunitinib—pancreatic cancer	0.00127	0.0299	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—CCKAR—pancreatic cancer	0.00125	0.0215	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Sunitinib—pancreatic cancer	0.0012	0.0282	CcSEcCtD
Azilsartan medoxomil—Candesartan—AGTR1—pancreatic cancer	0.00109	0.154	CrCbGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—PRLHR—pancreatic cancer	0.00104	0.0179	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—MET—pancreatic cancer	0.00101	0.0174	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—EGF—pancreatic cancer	0.000941	0.0161	CbGpPWpGaD
Azilsartan medoxomil—Blood creatinine increased—Tamoxifen—pancreatic cancer	0.000932	0.022	CcSEcCtD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—TGFB1—pancreatic cancer	0.000931	0.016	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—SSTR3—pancreatic cancer	0.000885	0.0152	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—SSTR1—pancreatic cancer	0.000848	0.0146	CbGpPWpGaD
Azilsartan medoxomil—Telmisartan—PPARG—pancreatic cancer	0.000848	0.121	CrCbGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—PPY—pancreatic cancer	0.000832	0.0143	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—SSTR2—pancreatic cancer	0.000817	0.014	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—PRLHR—pancreatic cancer	0.000815	0.014	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—CCKBR—pancreatic cancer	0.000799	0.0137	CbGpPWpGaD
Azilsartan medoxomil—Blood creatinine increased—Sunitinib—pancreatic cancer	0.000799	0.0189	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCKBR—pancreatic cancer	0.000789	0.0135	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCKBR—pancreatic cancer	0.000714	0.0123	CbGpPWpGaD
Azilsartan medoxomil—Losartan—AGTR1—pancreatic cancer	0.0007	0.0996	CrCbGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.000698	0.012	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—SSTR3—pancreatic cancer	0.000693	0.0119	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—CDH1—pancreatic cancer	0.000692	0.0119	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GAST—pancreatic cancer	0.000687	0.0118	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Tamoxifen—pancreatic cancer	0.000678	0.016	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Erlotinib—pancreatic cancer	0.000669	0.0158	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—SSTR1—pancreatic cancer	0.000664	0.0114	CbGpPWpGaD
Azilsartan medoxomil—Blood creatinine increased—Irinotecan—pancreatic cancer	0.000658	0.0155	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Gemcitabine—pancreatic cancer	0.000641	0.0151	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—SSTR2—pancreatic cancer	0.000639	0.011	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—pancreatic cancer	0.000634	0.0109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—CCK—pancreatic cancer	0.000621	0.0107	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCKBR—pancreatic cancer	0.000617	0.0106	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—pancreatic cancer	0.000614	0.0105	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCK—pancreatic cancer	0.000613	0.0105	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—CCKAR—pancreatic cancer	0.000596	0.0102	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.000594	0.0102	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CCKAR—pancreatic cancer	0.000588	0.0101	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—SRC—pancreatic cancer	0.000584	0.01	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Sunitinib—pancreatic cancer	0.000581	0.0137	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Sunitinib—pancreatic cancer	0.000579	0.0137	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Tamoxifen—pancreatic cancer	0.000576	0.0136	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.000569	0.00976	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.000558	0.00958	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCK—pancreatic cancer	0.000556	0.00953	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.000548	0.0094	CbGpPWpGaD
Azilsartan medoxomil—Angioedema—Tamoxifen—pancreatic cancer	0.000548	0.0129	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Sunitinib—pancreatic cancer	0.000535	0.0126	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—pancreatic cancer	0.000533	0.00914	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PRLHR—pancreatic cancer	0.000532	0.00912	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.000529	0.00908	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—EGFR—pancreatic cancer	0.000512	0.00879	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—CTNNB1—pancreatic cancer	0.000511	0.00876	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.000501	0.0118	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Sunitinib—pancreatic cancer	0.000494	0.0117	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Epirubicin—pancreatic cancer	0.000486	0.0115	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Irinotecan—pancreatic cancer	0.000477	0.0113	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Erlotinib—pancreatic cancer	0.000475	0.0112	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Erlotinib—pancreatic cancer	0.00047	0.0111	CcSEcCtD
Azilsartan medoxomil—Angioedema—Sunitinib—pancreatic cancer	0.000469	0.0111	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	0.000468	0.00803	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Gemcitabine—pancreatic cancer	0.000466	0.011	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Gemcitabine—pancreatic cancer	0.000465	0.011	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—SST—pancreatic cancer	0.000465	0.00798	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	0.00046	0.0079	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Epirubicin—pancreatic cancer	0.000459	0.0108	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—SSTR3—pancreatic cancer	0.000452	0.00776	CbGpPWpGaD
Azilsartan medoxomil—Hyperuricaemia—Doxorubicin—pancreatic cancer	0.00045	0.0106	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Irinotecan—pancreatic cancer	0.000441	0.0104	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.000434	0.0103	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—SSTR1—pancreatic cancer	0.000433	0.00744	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Gemcitabine—pancreatic cancer	0.000429	0.0101	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PPY—pancreatic cancer	0.000425	0.00729	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Doxorubicin—pancreatic cancer	0.000425	0.01	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.000422	0.00997	CcSEcCtD
Azilsartan medoxomil—Fatigue—Tamoxifen—pancreatic cancer	0.000422	0.00996	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GCG—pancreatic cancer	0.00042	0.0072	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000418	0.00987	CcSEcCtD
Azilsartan medoxomil—Fatigue—Erlotinib—pancreatic cancer	0.000417	0.00985	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—SSTR2—pancreatic cancer	0.000417	0.00716	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.000411	0.00706	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Sunitinib—pancreatic cancer	0.000411	0.0097	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Sunitinib—pancreatic cancer	0.000407	0.00961	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Irinotecan—pancreatic cancer	0.000407	0.0096	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCKBR—pancreatic cancer	0.000403	0.00691	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.000401	0.00688	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.000394	0.00677	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—pancreatic cancer	0.000375	0.00644	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—pancreatic cancer	0.000367	0.00629	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL8—pancreatic cancer	0.000365	0.00627	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000362	0.00854	CcSEcCtD
Azilsartan medoxomil—Fatigue—Sunitinib—pancreatic cancer	0.000361	0.00853	CcSEcCtD
Azilsartan medoxomil—Asthenia—Tamoxifen—pancreatic cancer	0.000351	0.00829	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP3—pancreatic cancer	0.00035	0.006	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000348	0.00823	CcSEcCtD
Azilsartan medoxomil—Asthenia—Erlotinib—pancreatic cancer	0.000347	0.0082	CcSEcCtD
Azilsartan medoxomil—Pruritus—Tamoxifen—pancreatic cancer	0.000346	0.00817	CcSEcCtD
Azilsartan medoxomil—Pruritus—Erlotinib—pancreatic cancer	0.000342	0.00809	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Irinotecan—pancreatic cancer	0.000338	0.00799	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	0.000336	0.00576	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Tamoxifen—pancreatic cancer	0.000335	0.0079	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—pancreatic cancer	0.000334	0.00574	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Erlotinib—pancreatic cancer	0.000331	0.00782	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Docetaxel—pancreatic cancer	0.000331	0.00781	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Docetaxel—pancreatic cancer	0.00033	0.00779	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00033	0.00779	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—SCT—pancreatic cancer	0.000328	0.00563	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Gemcitabine—pancreatic cancer	0.000327	0.00771	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000324	0.00766	CcSEcCtD
Azilsartan medoxomil—Dizziness—Tamoxifen—pancreatic cancer	0.000323	0.00764	CcSEcCtD
Azilsartan medoxomil—Dizziness—Erlotinib—pancreatic cancer	0.00032	0.00756	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCK—pancreatic cancer	0.000313	0.00538	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.000312	0.00535	CbGpPWpGaD
Azilsartan medoxomil—Rash—Tamoxifen—pancreatic cancer	0.000308	0.00728	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Tamoxifen—pancreatic cancer	0.000308	0.00728	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000307	0.00724	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CNR2—pancreatic cancer	0.000305	0.00524	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GLP1R—pancreatic cancer	0.000305	0.00524	CbGpPWpGaD
Azilsartan medoxomil—Rash—Erlotinib—pancreatic cancer	0.000305	0.00721	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Erlotinib—pancreatic cancer	0.000305	0.0072	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Docetaxel—pancreatic cancer	0.000305	0.0072	CcSEcCtD
Azilsartan medoxomil—Asthenia—Sunitinib—pancreatic cancer	0.000301	0.0071	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CCKAR—pancreatic cancer	0.0003	0.00515	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000298	0.00704	CcSEcCtD
Azilsartan medoxomil—Fatigue—Irinotecan—pancreatic cancer	0.000298	0.00703	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—pancreatic cancer	0.000297	0.00509	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Sunitinib—pancreatic cancer	0.000296	0.007	CcSEcCtD
Azilsartan medoxomil—Nausea—Tamoxifen—pancreatic cancer	0.000291	0.00686	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00029	0.00685	CcSEcCtD
Azilsartan medoxomil—Fatigue—Gemcitabine—pancreatic cancer	0.00029	0.00685	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.000288	0.00494	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Erlotinib—pancreatic cancer	0.000287	0.00679	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Sunitinib—pancreatic cancer	0.000287	0.00677	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000285	0.00674	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000284	0.0067	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Docetaxel—pancreatic cancer	0.000281	0.00664	CcSEcCtD
Azilsartan medoxomil—Dizziness—Sunitinib—pancreatic cancer	0.000277	0.00654	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—SHH—pancreatic cancer	0.000274	0.0047	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—pancreatic cancer	0.000273	0.00469	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PRLHR—pancreatic cancer	0.000273	0.00468	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TGFB1—pancreatic cancer	0.000272	0.00467	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—IAPP—pancreatic cancer	0.00027	0.00464	CbGpPWpGaD
Azilsartan medoxomil—Rash—Sunitinib—pancreatic cancer	0.000264	0.00624	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Sunitinib—pancreatic cancer	0.000264	0.00623	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTCH1—pancreatic cancer	0.00026	0.00445	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTHLH—pancreatic cancer	0.00026	0.00445	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—SSTR3—pancreatic cancer	0.000255	0.00438	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—pancreatic cancer	0.000254	0.00436	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GDI1—pancreatic cancer	0.00025	0.00429	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GDI2—pancreatic cancer	0.00025	0.00429	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Sunitinib—pancreatic cancer	0.000249	0.00588	CcSEcCtD
Azilsartan medoxomil—Asthenia—Irinotecan—pancreatic cancer	0.000248	0.00585	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000247	0.00584	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000245	0.0042	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Gemcitabine—pancreatic cancer	0.000241	0.0057	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PPY—pancreatic cancer	0.00024	0.00412	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Gemcitabine—pancreatic cancer	0.000238	0.00562	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—SST—pancreatic cancer	0.000237	0.00407	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Irinotecan—pancreatic cancer	0.000236	0.00558	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000236	0.00404	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Docetaxel—pancreatic cancer	0.000234	0.00553	CcSEcCtD
Azilsartan medoxomil—Pruritus—Fluorouracil—pancreatic cancer	0.000234	0.00552	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—SSTR3—pancreatic cancer	0.000232	0.00398	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Docetaxel—pancreatic cancer	0.000232	0.00547	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Gemcitabine—pancreatic cancer	0.00023	0.00543	CcSEcCtD
Azilsartan medoxomil—Dizziness—Irinotecan—pancreatic cancer	0.000228	0.00539	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000228	0.00391	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Fluorouracil—pancreatic cancer	0.000226	0.00534	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Epirubicin—pancreatic cancer	0.000223	0.00527	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000223	0.00526	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—SSTR1—pancreatic cancer	0.000222	0.00382	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CNR1—pancreatic cancer	0.000219	0.00376	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Fluorouracil—pancreatic cancer	0.000219	0.00516	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PPY—pancreatic cancer	0.000218	0.00374	CbGpPWpGaD
Azilsartan medoxomil—Rash—Irinotecan—pancreatic cancer	0.000218	0.00514	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Irinotecan—pancreatic cancer	0.000217	0.00513	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—SSTR2—pancreatic cancer	0.000214	0.00367	CbGpPWpGaD
Azilsartan medoxomil—Rash—Gemcitabine—pancreatic cancer	0.000212	0.00501	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Gemcitabine—pancreatic cancer	0.000212	0.005	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GCG—pancreatic cancer	0.000212	0.00363	CbGpPWpGaD
Azilsartan medoxomil—Rash—Fluorouracil—pancreatic cancer	0.000208	0.00492	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Fluorouracil—pancreatic cancer	0.000208	0.00492	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCKBR—pancreatic cancer	0.000207	0.00355	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000206	0.00488	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000206	0.00486	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000206	0.00486	CcSEcCtD
Azilsartan medoxomil—Fatigue—Docetaxel—pancreatic cancer	0.000206	0.00486	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Epirubicin—pancreatic cancer	0.000205	0.00485	CcSEcCtD
Azilsartan medoxomil—Nausea—Irinotecan—pancreatic cancer	0.000205	0.00484	CcSEcCtD
Azilsartan medoxomil—Nausea—Gemcitabine—pancreatic cancer	0.0002	0.00472	CcSEcCtD
Azilsartan medoxomil—Nausea—Fluorouracil—pancreatic cancer	0.000196	0.00464	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GAST—pancreatic cancer	0.000196	0.00336	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Doxorubicin—pancreatic cancer	0.00019	0.00449	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Epirubicin—pancreatic cancer	0.00019	0.00448	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—SCT—pancreatic cancer	0.000186	0.00318	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	0.000181	0.00311	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GAST—pancreatic cancer	0.000178	0.00305	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCK—pancreatic cancer	0.000177	0.00304	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Doxorubicin—pancreatic cancer	0.000175	0.00414	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CNR2—pancreatic cancer	0.000173	0.00296	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000173	0.00296	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Docetaxel—pancreatic cancer	0.000171	0.00404	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CCKAR—pancreatic cancer	0.00017	0.00291	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Docetaxel—pancreatic cancer	0.000169	0.00399	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—SCT—pancreatic cancer	0.000169	0.00289	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000167	0.00394	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Docetaxel—pancreatic cancer	0.000163	0.00386	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRLHR—pancreatic cancer	0.000161	0.00277	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCK—pancreatic cancer	0.000161	0.00276	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Epirubicin—pancreatic cancer	0.000158	0.00373	CcSEcCtD
Azilsartan medoxomil—Dizziness—Docetaxel—pancreatic cancer	0.000158	0.00373	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CNR2—pancreatic cancer	0.000157	0.00269	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GLP1R—pancreatic cancer	0.000157	0.00269	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Epirubicin—pancreatic cancer	0.000156	0.00369	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000154	0.00364	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CCKAR—pancreatic cancer	0.000154	0.00264	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IAPP—pancreatic cancer	0.000153	0.00262	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ACVR1B—pancreatic cancer	0.000152	0.0026	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ZNRF3—pancreatic cancer	0.000152	0.0026	CbGpPWpGaD
Azilsartan medoxomil—Rash—Docetaxel—pancreatic cancer	0.00015	0.00355	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Docetaxel—pancreatic cancer	0.00015	0.00355	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000147	0.00252	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000146	0.00345	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Doxorubicin—pancreatic cancer	0.000145	0.00342	CcSEcCtD
Azilsartan medoxomil—Nausea—Docetaxel—pancreatic cancer	0.000142	0.00335	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—SHH—pancreatic cancer	0.000141	0.00241	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000139	0.00328	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IAPP—pancreatic cancer	0.000139	0.00238	CbGpPWpGaD
Azilsartan medoxomil—Fatigue—Epirubicin—pancreatic cancer	0.000139	0.00328	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—DTX1—pancreatic cancer	0.000137	0.00235	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SSTR3—pancreatic cancer	0.000137	0.00235	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—SST—pancreatic cancer	0.000134	0.0023	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTHLH—pancreatic cancer	0.000133	0.00229	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTCH1—pancreatic cancer	0.000133	0.00229	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.000132	0.00226	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SSTR1—pancreatic cancer	0.000131	0.00225	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PPY—pancreatic cancer	0.000129	0.00221	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000129	0.00304	CcSEcCtD
Azilsartan medoxomil—Fatigue—Doxorubicin—pancreatic cancer	0.000128	0.00303	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SSTR2—pancreatic cancer	0.000126	0.00217	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CNR1—pancreatic cancer	0.000124	0.00212	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCKBR—pancreatic cancer	0.000122	0.0021	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—SST—pancreatic cancer	0.000122	0.00209	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000121	0.00208	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.00012	0.00206	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GCG—pancreatic cancer	0.00012	0.00205	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000116	0.002	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Epirubicin—pancreatic cancer	0.000115	0.00273	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—DTX4—pancreatic cancer	0.000115	0.00197	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GLI1—pancreatic cancer	0.000115	0.00197	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Epirubicin—pancreatic cancer	0.000114	0.00269	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000113	0.00194	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CNR1—pancreatic cancer	0.000112	0.00193	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NRP1—pancreatic cancer	0.000112	0.00192	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000112	0.00192	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Epirubicin—pancreatic cancer	0.00011	0.0026	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GCG—pancreatic cancer	0.000109	0.00186	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HEY2—pancreatic cancer	0.000108	0.00184	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Doxorubicin—pancreatic cancer	0.000107	0.00252	CcSEcCtD
Azilsartan medoxomil—Dizziness—Epirubicin—pancreatic cancer	0.000106	0.00251	CcSEcCtD
Azilsartan medoxomil—Pruritus—Doxorubicin—pancreatic cancer	0.000105	0.00249	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GAST—pancreatic cancer	0.000105	0.0018	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000104	0.00179	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Doxorubicin—pancreatic cancer	0.000102	0.00241	CcSEcCtD
Azilsartan medoxomil—Rash—Epirubicin—pancreatic cancer	0.000101	0.0024	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Epirubicin—pancreatic cancer	0.000101	0.00239	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SCT—pancreatic cancer	9.96e-05	0.00171	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HEY1—pancreatic cancer	9.96e-05	0.00171	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Doxorubicin—pancreatic cancer	9.85e-05	0.00233	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	9.63e-05	0.00165	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Epirubicin—pancreatic cancer	9.56e-05	0.00226	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCK—pancreatic cancer	9.5e-05	0.00163	CbGpPWpGaD
Azilsartan medoxomil—Rash—Doxorubicin—pancreatic cancer	9.39e-05	0.00222	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Doxorubicin—pancreatic cancer	9.38e-05	0.00222	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GLP1R—pancreatic cancer	9.26e-05	0.00159	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CNR2—pancreatic cancer	9.26e-05	0.00159	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL8—pancreatic cancer	9.25e-05	0.00159	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCKAR—pancreatic cancer	9.11e-05	0.00156	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Doxorubicin—pancreatic cancer	8.84e-05	0.00209	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JAG2—pancreatic cancer	8.83e-05	0.00152	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MEN1—pancreatic cancer	8.7e-05	0.00149	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SHH—pancreatic cancer	8.3e-05	0.00142	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH4—pancreatic cancer	8.25e-05	0.00142	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IAPP—pancreatic cancer	8.2e-05	0.00141	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTHLH—pancreatic cancer	7.87e-05	0.00135	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTCH1—pancreatic cancer	7.87e-05	0.00135	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SST—pancreatic cancer	7.2e-05	0.00124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CG—pancreatic cancer	7.1e-05	0.00122	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JAG1—pancreatic cancer	7.04e-05	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH3—pancreatic cancer	7.01e-05	0.0012	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CNR1—pancreatic cancer	6.64e-05	0.00114	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CG—pancreatic cancer	6.45e-05	0.00111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GCG—pancreatic cancer	6.42e-05	0.0011	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.24e-05	0.00107	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STK11—pancreatic cancer	6.03e-05	0.00103	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CD—pancreatic cancer	5.67e-05	0.000972	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.44e-05	0.000933	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SMAD4—pancreatic cancer	5.28e-05	0.000906	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL8—pancreatic cancer	5.23e-05	0.000897	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HES1—pancreatic cancer	5.16e-05	0.000885	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CB—pancreatic cancer	4.94e-05	0.000848	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL8—pancreatic cancer	4.75e-05	0.000815	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TERT—pancreatic cancer	4.52e-05	0.000776	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIF1A—pancreatic cancer	4.32e-05	0.000742	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TSC2—pancreatic cancer	4.31e-05	0.00074	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOE—pancreatic cancer	4.22e-05	0.000724	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KDR—pancreatic cancer	4.13e-05	0.000709	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NFKBIA—pancreatic cancer	3.93e-05	0.000675	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH1—pancreatic cancer	3.89e-05	0.000668	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CG—pancreatic cancer	3.81e-05	0.000653	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—NRAS—pancreatic cancer	3.81e-05	0.000653	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGF—pancreatic cancer	3.76e-05	0.000646	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EGFR—pancreatic cancer	3.47e-05	0.000595	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CD—pancreatic cancer	3.35e-05	0.000574	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.32e-05	0.000569	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KRAS—pancreatic cancer	3.28e-05	0.000562	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CA—pancreatic cancer	3.01e-05	0.000517	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CB—pancreatic cancer	2.92e-05	0.000501	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL8—pancreatic cancer	2.8e-05	0.000481	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HRAS—pancreatic cancer	2.79e-05	0.000478	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT1—pancreatic cancer	2.71e-05	0.000465	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CASP3—pancreatic cancer	2.68e-05	0.000461	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCND1—pancreatic cancer	2.61e-05	0.000448	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CTNNB1—pancreatic cancer	2.59e-05	0.000444	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—pancreatic cancer	2.54e-05	0.000435	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTEN—pancreatic cancer	2.52e-05	0.000433	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT1—pancreatic cancer	2.46e-05	0.000422	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SRC—pancreatic cancer	2.34e-05	0.000401	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—pancreatic cancer	2.28e-05	0.000391	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—pancreatic cancer	2.26e-05	0.000387	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NRAS—pancreatic cancer	2.25e-05	0.000386	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYC—pancreatic cancer	2.1e-05	0.00036	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFB1—pancreatic cancer	2.09e-05	0.000359	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGFR—pancreatic cancer	2.05e-05	0.000352	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KRAS—pancreatic cancer	1.94e-05	0.000332	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CA—pancreatic cancer	1.78e-05	0.000305	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TP53—pancreatic cancer	1.72e-05	0.000295	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HRAS—pancreatic cancer	1.65e-05	0.000282	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT1—pancreatic cancer	1.45e-05	0.000249	CbGpPWpGaD
